TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02297711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total ExtraPeritoneal
Description: This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open minimal suture repair
Description: This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
Study: NCT04307368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elimination-rotational diet
Description: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic diet
Description: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
Study: NCT02997696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ONO-4474
Study: NCT02107625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet A i.e. Low FODMAP diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet B, i.e. Traditional IBS diet
Study: NCT03042650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Referral Intervention Group
Description: The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Facilitated Group
Description: The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
Study: NCT03404063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac Drug
Description: Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Study: NCT01186887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Study: NCT01802580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Survey
Study: NCT01299740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participation in DBT Skills Group
Description: Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Treatment as usual
Study: NCT03447704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Description: 120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
Study: NCT01802580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinonide 0.05% ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinonide 0.05% ointment
Study: NCT02471118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Description: Adalimumab will be self-administered via subcutaneous (SC) injection
Study: NCT04332146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program (MBI-p-R)
Description: The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet-based psychoeducation
Description: The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
Study: NCT04502693

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ vaccine
Description: rMenB+OMV NZ vaccine was administered intramuscularly.
Study: NCT02471118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Description: Adalimumab will be self-administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered via subcutaneous (SC) injection
Study: NCT04502693

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ vaccine
Description: rMenB+OMV NZ vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ vaccine
Description: rMenB+OMV NZ vaccine was administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: MenACWY vaccine was administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: MenACWY vaccine was administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: MenACWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered intramuscularly.
Study: NCT02471118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered via subcutaneous (SC) injection
Study: NCT00292201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
Study: NCT01088295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study: NCT00964483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure.
Study: NCT00661726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (USAN, INN)
Description: Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
Study: NCT04244695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
Study: NCT04502693

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered intramuscularly.
Study: NCT01248572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softec HD IOL
Description: Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
Study: NCT03529617

Intervention type: OTHER
Intervention: Sample collection
Description: Plasma, urine, BAL and ascitic fluid sample collection.

Intervention type: OTHER
Intervention: Sample collection
Description: Plasma, urine, BAL and ascitic fluid sample collection.
Study: NCT02085044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Used Supplement Food administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-Used Supplement Food administration
Study: NCT01846299

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Study: NCT01321255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC
Description: FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Separately drugs, simvastatin, aspirin and ramipril
Description: Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
Study: NCT02463708

Intervention type: BEHAVIORAL
Intervention: BHL COTP
Description: The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
Study: NCT04290247

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging for fracture diagnosis before conventional X-ray
Study: NCT02065843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulungu
Description: 500 mg/single dose/1 hour before dental surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/single dose/1 hour before dental surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Passiflora incarnata
Description: 100 mg/single dose/1 hour before dental surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: 15 mg/single dose/1 hour before dental surgery
Study: NCT04502693

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-1
Description: Lot 1 of the MenABCWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-1
Description: Lot 1 of the MenABCWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2
Description: Lot 2 of the MenABCWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2
Description: Lot 2 of the MenABCWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-3
Description: Lot 3 of the MenABCWY vaccine was administered intramuscularly.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-3
Description: Lot 3 of the MenABCWY vaccine was administered intramuscularly.
Study: NCT00816530

Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Description: After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
Study: NCT01893164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple decompression
Description: decompression of the ulnar nerve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple decompression
Description: decompression of the ulnar nerve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior subcutaneous transposition
Description: transposition of the ulnar nerve into subcutaneous bed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior subcutaneous transposition
Description: transposition of the ulnar nerve into subcutaneous bed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior intramuscular transposition
Description: transposition of the ulnar nerve into muscular tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior intramuscular transposition
Description: transposition of the ulnar nerve into muscular tissue
Study: NCT04352712

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling
Study: NCT03385005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.
Description: The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.
Description: The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
Study: NCT03350581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAM 3D map group
Description: Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FAM-CT 3D map group
Description: Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
Study: NCT05185193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency
Description: Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
Study: NCT04178486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with amnesia suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with cognitive rehearsal suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with memory substitution suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypnosis with induction only
Description: Participants received only hypnotic induction.
Study: NCT00896571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestogene (BAY86-5016)
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study: NCT02485197

Intervention type: OTHER
Group type: OTHER
Intervention: 7 continuous days of aerobic training
Description: For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.

Intervention type: OTHER
Group type: OTHER
Intervention: 7 continuous days of aerobic training
Description: For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
Study: NCT03342183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Description: Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
Study: NCT01284829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET scan
Study: NCT03718832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Food Farmacy
Description: Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
Study: NCT03504657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty
Description: Angioplasty with a drug-coated angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenting angioplasty
Description: Angioplasty with a stenting